23 research outputs found
Study on PPIUCD Acceptors and their Follow Up
Get PDFBACKGROUND :
India is world’s second most populated country with 1.3 billion people. It contributes 17.5% of the world’s population by adding 25 million births every year. Nearly 20.7% of the Indian population have unmet needs for family planning with 65% of the needs in the first year of postpartum period. Postpartum period is the ideal time of family planning. studies show that spacing less than two years of child birth can lead to obstetric complications and maternal mortality. Hence practice of contraception is mandatory. This study helps to determine the socio economic and demographic factors associated with postplacental insertion of copper T. It also helps to determine the complications. The intra uterine device is highly effective, safe, rapidly reversible, long acting, coital independent method of contraception with relatively few side effects. This is also known as coil.
With the increased number of institutional deliveries due to the provision of Janani suraksha yojana – a cash transfer scheme there is increased access to the
pregnant women for promoting family planning services. Further more in the immediate postpartum period, the insertion of intrauterine device is convenient and these women are highly motivated. The postplacental IUCD insertion is particularly suitable for our country where even para medical personnel can insert the cu T and delivery is the only time these patients come in contact with the hospital.
AIM OF THE STUDY :
The present study is aimed at determining the safety. efficacy and expulsion of postplacental insertion of Cu T 380A following vaginal deliveries, instrumental deliveries and caesarean section. In this study, the Cu T 380 A was inserted within 10 minutes of the delivery of placenta and their outcome studied.
OBJECTIVES :
1. To determine proportion of women accepting immediate PPIUCD insertin.
2. To determine the factors associated with acceptability including the socio
demographic and obstetric characters.
3. To determine the rates ofexpulsion, pelvicinfection, lost strings and misplacement
among the acceptors following the postplacental insertion and its outcome after six
weeks.
MATERIALS AND METHODS :
Study Design :
The study was a prospective observational study to assess the awareness,
acceptance and safety of PPIUCD use in women inserted 10 minutes following
deliveries.
Study Setting :
The study was conducted in the Department of Obstetrics and Gynaecology at
Government Theni Medical College Hospital, Theni, Tamilnadu.
Study Period : One year from August 2015 to July 2016.
Study Population:
1. All patients delivered during the study period fulfilling the inclusion criteria.
2. Mode of delivery can be vaginal, instrumental or by caesarean sections.
METHODOLOGY :
A structured open ended questionnaire was given to all patients participating
in the study.
• It includes socio demographic factors, antenatal history, awareness of
PPIUCD, reasons for acceptance
• Study was the insertion of IUCD (Cu T 380 A) immediately after the
delivery of the placenta following vaginal, instrumental or caesarean sections
At six weeks interval, the women are followed up to evaluate the
efficacy, complication and continuation
Inclusion Criteria :
1. Women counseled about PPIUCD and their willingness.
2. 19 - 35 year old mothers.
3. gestational age : 34 - 40 weeks.
4. haemoglobin more than or equal to 9gm%.
Exclusion Criteria:
1. Patients not willing for participation in the study.
2. History of angtepartum haemorrhage.
3. History of rupture of membranes > 12 hours.
4. Any lower genital tract infection.
5. Uterine anomalies.
6. History of post partum haemorrhage.
RESULTS :
Total women counselled – 1150, Accepted – 500, Declined – 650, Lost to follow up – 18, Followed up – 482, Complications - 104, (Expulsion = 23, Bleeding = 45, String problem= 24, abdominal pain =12), Removal - 42, Continuation – 417.
CONCLUSION:
The PPIUCD is particularly safe with few complications as demonstrated in the
study. The patients should be counselled regarding the advantages even in the
antenatal clinic itself as successful family planning measures helps to avert 20-35%
of maternal deaths and nearly 20% of neonatal deaths
Antimicrobial, Antioxidant and Cytotoxic Activity of MarineStreptomyces parvulus VITJS11 Crude Extract
No full textThe main aim of the study was to evaluate the bioactive properties of ethyl acetate crude extract of Streptomyces parvulus VITJS11 with a view to assess their therapeutic potential. The biological activity of ethyl acetate extract was tested against fungal and bacterial pathogens. The free radical scavenging potential of the crude extract was determined by DPPH assay. The chemo preventive properties of S. parvulus VITJS11 ethyl acetate extract was examined by MTT assay on HepG2 cells. The morphological, physiological and the biochemical properties of the strain S. parvulus VITJS11 was confirmed by conventional methods. Genotypic characterization was done using 16S r-DNA partial gene amplification and sequencing. The authenticity of the crude chemical constitutes were determined by the GC-MS. The ethyl acetate extract of VITJS11 showed maximum antifungal activity against three Aspergillus species and prominent antibacterial activity against two Gram positive and Gram negative bacteria at 20 mg/mL. The antioxidant potential of the crude extract exhibited strong reducing power activity at 5mg/ mL with 85% inhibition and the cytotoxic effect was found with IC50 of 500µg/ mL on HepG2 cell lines. The GC-MS analysis and the chromatogram patterns revealed 16 peaks, indicating the presence of bioactive constituents, which included several important organic compounds, namely 9-(2',2'-dimethylpropanoilhydrazono)-3,6-dichloro-2,7-Bis-[2-(diethylamino)-ethoxy]fluorine (23.1) Dotriacontylpentafluoropropionate,(25.0) Octadecanoic acid, (20.0); Trans-2-methyl-4-n-butylthiane, S, S-dioxide.(19.0). The results showed the benefit of ethyl acetate extract from S. parvulus VITJS11 in treating microbial infections and indicated their broad spectrum of activity with beneficial virtues for therapeutic use
Biosynthesis and therapeutic applications of MK-7: A comprehensive review
No full textThe fat-soluble vitamin K is an indispensable cofactor that transmutes the glutamic acid residues to -γ-carboxyglutamic residues in blood and bones. Vitamin K is further classified into three namely, Phylloquinone, Menaquinone and Menadione. Both, phylloquinone and menaquinone are naturally derived types of vitamin K while Menadione is a synthetic variant. Among the several types of vitamin K, Menaquinone-7 (MK-7) stands out because of its extended half-life. MK-7 is found to have potential therapeutic effects in preventing cardiovascular disease, osteoporosis, diabetes, Alzheimer and cancer. Comprehending the diverse functions of MK-7 provides valuable perspectives on its ability to enhance overall health. During microbial fermentation, certain strains are selected and improved for effective synthesis of MK-7. Researchers are investigating industrial-scale production techniques such as fermentation conditions, downstream processing, and purification methods to increase both quantity and quality. This review highlights MK-7’s diverse biological functions and industrial significance, emphasizing advancements in microbial fermentation, including strain improvement and production optimization, to enhance yield and quality
In vitro thrombolytic potential of bioactive compounds from marine Streptomyces sp. VITJS4
Get PDFThe most practical approach to reduce morbidity and mortality of coronary heart disease (CHD) is to delay the process of thrombus by usage of clot-dissolving agents. The necessities of such safer compounds are to be critically examined for thrombolytic activity especially, from marine sources. Thrombolytic agents have been investigated as a possible treatment for thrombus. The aim of this study was to investigate the in vitro thrombolytic potential of Streptomyces sp.VITJS4 (NCIM No. 5574); (ACC No: JQ234978.1) active compounds. The fibrin degradation revealed a clear transparent zone of clearance with 500μg/mL concentration showing 24mm hydrolysis. The thrombolytic effect of Streptomyces sp.VITJS4 compounds was also demonstrated in vitro clot lysis assay where The percent of thrombolysis by the crude extract showed 90±1.7% at the concentration of 1000µg/mL,  whereas percent of thrombolysis by streptokinase was found 100± 00%%. The bioactive compounds were further studied for spectrophotometric analysis. The UV-VIS profile showed different peaks ranging from 400-700 nm with different absorption respectively. The data confirmed the presence of both analogues with absorption maxima at 210 and 310 nm. A sensitive method using LC-MS technique was optimized for the separation and identification of bioactive metabolites which was indicated by the fingerprints. The results of the LC-MS analysis provided different peaks determining the presence of compounds with different therapeutic activities.  The current study refers the bioactive compound as impressive thrombolytic agent for further laboratory study. Further studies should be conducted to ensure the efficacy and safety of different concentration of bioactive compounds for drug development. Hence the results reported perhaps useful for the discovery of novel thrombolytic drugs from marine origin
Molecular identification of autochthonous bacterial fibrinolytic protein producers from fermentative food preparations
No full text154-162The current study investigates screening, isolation and characterization of fibrinolytic enzyme producing autochthonous
bacteria from fermented foods. About 21 different fermented food samples were screened for fibrinolytic protease producing
bacteria. Procured and prepared samples were homogenized, serially diluted and plated onto nutrient agar and soybean
casein digest agar medium. A total number of 89 isolates were isolated and screened for caseinolytic and fibrinolytic
activities. Out of those 89 isolates, nineteen were found to be potent protease producers. Amongst those isolates MS2, MS3,
MS4 and MS9 had notable fibrinolytic activities as well. These isolates were subjected for biochemical and molecular
characterization to determine their taxonomy and phylogeny. The strain with highest fibrinolytic potency was found to be
Bacillus subtilis VITMS2 isolated from fermented milk of Vigna unguiculata. The clot lysing ability of the selected potent
strain B. subtilis was found to be 79.98%. The total and specific activity of the same was found to be 788.82 U/mL and
41.73 U/mg, respectively. Other strains with comparatively low fibrinolytic activity were Pseudomonas aeruginosa
VITMS3, Bacillus sp VITMS4 and Alcaligenes sp. VITMS9
Novel Fibrinolytic Protease Producing Streptomyces radiopugnans VITSD8 from Marine Sponges
No full textFibrinolytic enzymes have received more attention due to their medicinal potential for thrombolytic diseases. The aim of this study is to characterize the in vitro fibrinolytic nature of purified protease producing Streptomyces radiopugnans VITSD8 from marine brown tube sponges Agelas conifera. Three varieties of sponge were collected from the Rameshwaram Sea coast, Tamil Nadu, India. The fibrinolytic activity of Streptomyces sp. was screened and determined by casein plasminogen plate and fibrin plate methods respectively. The crude caseinolytic protease was purified using ammonium sulfate fractionation, affinity and ion-exchange chromatography. Based on the morphological, biochemical, and molecular characterization, the isolate VITSD8 was confirmed as Streptomyces radiopugnans. Maltose and peptone were found to be the best carbon and nitrogen sources for the production of fibrinolytic protease. The carbon and nitrogen source peptone showed (781 U/mL) enzyme activity. The optimum pH and temperature for fibrinolytic protease production was found to be 7.0 and 33 °C respectively. The purified enzyme showed a maximum specific activity of 3891 U. The blood clot lysis activity was compared with the standard, and it was concluded that a minimum of 0.18 U (10 µL) of purified protease was required to dissolve the blood clot. This is the first report which exploits the fibrinolytic protease activity of Streptomyces radiopugnans VITSD8 extracted from a marine sponge. Hence the investigation suggests a potential benefit of purified fibrinolytic protease which will serve as an excellent clot buster alternative
Formulation of cost-effective medium and optimization studies for enhanced production of rapamycin
No full textAbstract Background Enhancing rapamycin production using a cost-effective medium is crucial for wider accessibility, reduced manufacturing costs, sustainable pharmaceutical practices, and advancements in therapeutic applications. It promotes global health, biotechnological innovation, research collaboration, and societal well-being through affordable and effective treatments. This study focuses on the development of a novel cost-effective production medium for the synthesis of rapamycin from Streptomyces hygroscopicus. Results In the initial screening, more rapamycin production was observed in medium A. Initially, the organism produced 10 µg/mL rapamycin. Based on the OFT results, a novel cost-effective medium composition was designed, incorporating soyabean, sugarcane juice, and dried tomato components. Using RSM, soyabean and tomato was found to be more significant in rapamycin production than sugarcane. In the optimized medium, the production of rapamycin increased significantly to 24 µg/mL. Furthermore, a comparative analysis of the growth kinetics between the production normal medium (referred to as production medium A) and the newly optimized cost-effective production medium revealed that the optimized cost-effective production medium significantly enhanced the production of rapamycin. Conclusion Overall, this study demonstrates the successful development of a cost-effective production medium for rapamycin synthesis from S. hygroscopicus. The findings highlight the potential of using a cost-effective medium to enhance the production of a valuable secondary metabolite, rapamycin, while reducing production costs
Production of fibrinolytic protease from<i>Streptomyces lusitanus</i>isolated from marine sediments
No full text
